<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579394</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-CHIR101</org_study_id>
    <nct_id>NCT03579394</nct_id>
  </id_info>
  <brief_title>Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer</brief_title>
  <acronym>CHRONO</acronym>
  <official_title>CHRONO - Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of CHRONO trial is to compare the DFS when surgery is performed after 3 courses of
      NACT, or after 6 courses of NACT, in a prospective multi institutional randomized
      setting,considering only patients initially unsuitable for primary surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>From date of randomisation until the date of second cancer or death, which ever occurs earlier, assessed up to 5 years</time_frame>
    <description>Disease free survival (DFS) defined as the time interval between randomization and physical or radiographic evidence of recurrence (local/distant) or second cancer or death (all causes) whichever occur first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>through study completion, up to 2 years</time_frame>
    <description>Health related quality of life of the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (PCR)</measure>
    <time_frame>through study completion, up to 2 years</time_frame>
    <description>Pathological response will be established using the grading system called chemotherapy response score (CRS). The response will be assessed based on the omentum microscopic review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from date of randomisation to death, assessed up to 5 years</time_frame>
    <description>Overall survival (OS) defined as time interval between randomization and death (all causes); alive patients will be censored at the last date of news</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for first subsequent treatment (TFST)</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative mortality</measure>
    <time_frame>up to 5 months</time_frame>
    <description>Post operative mortality defined as the interval between the date of debulking surgery and the date of death due to any cause occurring within the 30 day post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity</measure>
    <time_frame>up to 5 months</time_frame>
    <description>Surgical morbidity defined as the interval between the date of debulking surgery and any events occurring within the 30 day post-surgery (All grades ≥ 3 according to the CTCAE v4.03 &amp; All grades ≥ 3 according to Clavien Dindo classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fagotti laparoscopic score</measure>
    <time_frame>diagnosis</time_frame>
    <description>Disease extension assessed by Fagotti score at the time of diagnosis https://www.ncbi.nlm.nih.gov/pubmed/16791447</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC-AE version 4.03 adverse events</measure>
    <time_frame>30 days after last treatment intake, up to 1 year</time_frame>
    <description>safety assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire OV28</measure>
    <time_frame>through study completion, up to 2 years</time_frame>
    <description>Physical, abdominal/gastrointestinal (GI), fatigue</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Ovarian Cancer Stage IV</condition>
  <condition>Ovarian Cancer Stage IIIC</condition>
  <condition>Ovarian Cancer Stage IIIb</condition>
  <arm_group>
    <arm_group_label>Interval Debulking Surgery (IDS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retarded Interval Debulking Surgery (IDS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retarded IDS (Interval Debulking Surgery)</intervention_name>
    <description>Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy
Treatment accepted :
Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):
paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or
paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or
paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21
Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)</description>
    <arm_group_label>Retarded Interval Debulking Surgery (IDS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard IDS (Interval Debulking Surgery)</intervention_name>
    <description>Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.
Treatment accepted :
Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):
paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or
paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or
paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21
Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)</description>
    <arm_group_label>Interval Debulking Surgery (IDS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients ≥18 years.

          2. Histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma or
             primary peritoneal carcinoma, high grade serous or endometrioïd, with the exception of
             mucinous, clear cell and carcinosarcoma histologies.

          3. Performance status &lt; 2 (see Appendix 2).

          4. Documented International Federation of Gynecologic Oncology (FIGO 2014, Appendix 1)
             stage IIIB-IIIC-IVa unsuitable for complete primary cytoreductive surgery (confirmed
             by open laparoscopy or by laparotomy [not mandatory for stage IVA]).

          5. Patient must be judged resectable after 3 courses of Neoadjuvant chemotherapy

          6. Adequate bone marrow, liver and renal function to receive chemotherapy and
             subsequently to undergo surgery:

               -  White blood cells (WBC) &gt;3x109/L, absolute neutrophil count (ANC) ≥1,5x109/L,
                  platelets (PLT)

                  ≥100x109/L, hemoglobin (Hb) ≥9 g/dL,

               -  Serum creatinine &lt;1.25 x upper normal limit (UNL) or creatinine clearance ≥ 30
                  mL/min according to Cockroft-Gault formula or to local lab measurement, serum
                  bilirubin &lt;1.25 x UNL, AST(SGOT) and ALT(SGPT) &lt;2.5 x UNL.

          7. Signed informed consent obtained prior to any study-specific procedures.

          8. Patient affiliated to, or a beneficiary of, a social security category

        Exclusion Criteria:

          1. Mucinous, clear cell , carcinosarcoma and low grade serous carcinomahistologies.

          2. Synchronous or previous other malignancies within 3 years prior to starting study
             treatment, with the exception of adequately treated non-melanomatous skin cancer or
             carcinoma in situ (of the cervix or breast or other sites).

          3. Patients with brain metastases, seizure not controlled with standard medical therapy,
             or history of cerebrovascular accident (CVA, stroke) or transient ischemic attack
             (TIA) or subarachnoid hemorrhage before 6 months from the enrollment on this study.

          4. Any other concurrent medical conditions contraindicating surgery or chemotherapy that
             could compromise the adherence to the protocol (including but not limited to impaired
             cardiac function or clinically significant cardiac diseases, active or uncontrolled
             infections, HIV-positive patients on antiretroviral therapy, uncontrolled diabetes,
             cirrhosis, chronic active or persistent hepatitis, impaired respiratory function
             requiring oxygen-dependence, serious psychiatric disorders).

          5. Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Classe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sidonie ADAM</last_name>
    <phone>+33(0)-1-84-85-20-20</phone>
    <email>sadam@arcagy.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICA - Polyclinique Urbain V</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeau</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan - Centre Hospitalier Universitaire</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François DUPRE</last_name>
      <phone>02 98 22 33 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine MARTIN-FRANCOISE</last_name>
      <phone>02 31 45 50 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe POMEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard - Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital de la Mère et de l'Enfant</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan GAUTHIER</last_name>
      <phone>05 55 05 61 64</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle CUMIN</last_name>
      <phone>02 97 64 91 93</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre MEEUS</last_name>
      <phone>04 78 78 27 43</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Neuilly-sur-seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel BARRANGER</last_name>
      <phone>04 92 03 14 37</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LECURU</last_name>
      <phone>01 56 09 35 85</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine UZAN</last_name>
      <phone>06 03 57 86 35</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin, Institut Curie</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman ROUZIER</last_name>
      <phone>01 47 11 15 15</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc CLASSE</last_name>
      <phone>02 40 67 99 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Médico-chirurgicale CHARCOT</name>
      <address>
        <city>Sainte Foy-les-Lyon</city>
        <zip>69110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas CARRABIN</last_name>
      <phone>04 72 32 30 21</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwénaël FERRON</last_name>
      <phone>05 31 15 53 55</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lobna OULDAMER</last_name>
      <phone>02 47 47 47 41</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>retarded surgery</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

